This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/kegg-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/pubchem-compound/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/kegg-drug/
n21http://www.drugs.com/mtm/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/drugbank/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00414/identifier/chemspider/

Statements

Subject Item
n2:DB00414
rdf:type
n3:Drug
n3:description
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
n3:group
withdrawn
n3:halfLife
Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.
n3:indication
Used in the management of diabetes mellitus type 2 (adult-onset).
n3:manufacturer
n15:271B4720-363D-11E5-9242-09173F13E4C5 n15:271B4721-363D-11E5-9242-09173F13E4C5 n15:271B471E-363D-11E5-9242-09173F13E4C5 n15:271B471F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00414 n23:DB00414
dcterms:title
Acetohexamide
adms:identifier
n6:46505821 n7:1989 n8:C06806 n9:D00219 n10:DB00414 n11:28052 n12:1912 n16:Acetohexamide n19:PA164777011
n3:mechanismOfAction
Sulfonylureas such as acetohexamide bind to an ATP-dependent K<sup>+</sup> channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca<sup>2+</sup> channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.
n3:packager
n15:271B471C-363D-11E5-9242-09173F13E4C5 n15:271B471D-363D-11E5-9242-09173F13E4C5
n3:synonym
Acétohexamide 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea Acetohexamid 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide Acetohexamidum Acetohexamide Acetohexamida N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea
n3:toxicity
Oral, rat LD<sub>50</sub>: 5 gm/kg; Oral, mouse LD<sub>50</sub>: >2500 mg/kg. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma.
n3:foodInteraction
Avoid alcohol. Take without regard to meals.
n3:proteinBinding
90%
n17:hasConcept
n18:M0000136
foaf:page
n21:acetohexamide.html
n3:IUPAC-Name
n4:271B4726-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B472C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B472B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4728-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4729-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B472A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4724-363D-11E5-9242-09173F13E4C5 n4:271B473C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4722-363D-11E5-9242-09173F13E4C5 n4:271B4725-363D-11E5-9242-09173F13E4C5 n4:271B473E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B473F-363D-11E5-9242-09173F13E4C5 n4:271B4723-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4732-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4733-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B472D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B472E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4730-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B472F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4731-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed from the GI tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
968-81-0
n3:category
n3:Bioavailability
n4:271B4738-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B473A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B473B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B473D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4737-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4736-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4739-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4727-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4734-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4735-363D-11E5-9242-09173F13E4C5